Evergreening: Big Pharma's big con
Practice of extending patents stifles competition and can increase the cost of vital drugs to those most in need
US pharmaceutical giant Johnson & Johnson (J&J) is to be investigated by South Africa's Competition Commission over the high price of its tuberculosis medicine, bedaquiline, and attempts to extend its patent through a controversial practice known as "evergreening".
What is this?
Evergreening is when brand-name pharmaceutical companies patent "new inventions" that are in reality minor modifications of old drugs.
These could include new forms of release, new dosages, new combinations or variations. Big Pharma refers to this as "lifecycle management" and it effectively means drug manufacturers can make "trivial changes to medicines or their use in order to keep their monopoly in the market", said The Guardian.
Subscribe to The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.
Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
This practice is widespread across the industry and has increased over time. A research paper published in 2018 titled "May Your Drug Price Be Evergreen" in the Journal of Law and the Biosciences found that 78% of the drugs in the US associated with new patents between 2005 and 2015 were not new drugs but existing ones. "Once companies start down the road of extending protection, they show a tendency to return to the well, with the majority adding more than one extension and 50% becoming serial offenders," said the study.
In one high-profile example, AbbVie's arthritis treatment, Humira – the world's most popular drug – was revealed to have more than 100 patents, Reuters reported. Critics allege that these “patent thickets” delay the launch of rival generic medicines even after exclusivity periods have elapsed for the original patent, explained the Financial Times.
In the case of bedaquiline – the world's leading treatment for multi-drug resistant tuberculosis (TB) – J&J was able to extend its patent, which expired in July in many low- and middle-income countries (LMICs), to 2027 because of so-called secondary patents on tweaks to the drug's formulation that improve its absorption in the body.
Why is it so controversial?
Evergreening helps Big Pharma protect some of its most prized assets but "since branded drugs are winning lengthy and lucrative IP [intellectual property] extensions, generics are taking longer to reach the market and prices around the industry continue to rise", reported industry news site Fierce Pharma.
South Africa has one of the highest TB rates in the world, and "even though TB is curable – it is the country's leading cause of death", said The Guardian. That is why the country's Fix the Patent Laws campaign has argued such practices have "acted as a barrier to equitable and affordable access to medicines for HIV, tuberculosis, mental health, diabetes and cancer".
Russell Rensburg, the director of the Rural Health Advocacy Project at Wits University in Johannesburg, put it more bluntly, claiming countering "these kinds of exploitative practices" is "essential to addressing health inequity".
Are things finally changing?
Having long flown under the radar, the issue of patent evergreening is attracting wider attention from regulators and lawmakers.
Delivering what Science magazine called a "key victory" for advocates of affordable access to bedaquiline, in March 2023 the Indian Patent Office rejected J&J's attempt to win a secondary patent to extend its exclusivity until 2027.
Had it accepted the patent, "public and family budgets would have remained burdened by unjustifiable high costs of the drug", said the People's Dispatch.
Then this summer, J&J announced a deal in conjunction with the UN-affiliated Stop TB Partnership not to enforce some of its patents on the drug, in a move that makes generic versions available in many low- and middle-income countries, lowering costs. But South Africa has an open tender system so cannot legally buy medicine through the wider system, meaning it "doesn't appear to be benefiting from the slide in prices", reported Managing IP.
In a statement, J&J said it was a "longstanding and committed partner in South Africa's fight against multidrug-resistant tuberculosis" and that all patients in the country who require bedaquiline have access to it thanks to the company's collaboration with the government and other partners.
Sign up for Today's Best Articles in your inbox
A free daily email with the biggest news stories of the day – and the best features from TheWeek.com
-
Spotify Wrapped: a slave to the algorithm?
Talking Point Some listeners aren't convinced by the streaming platform's AI features – or what they say about their music habits
By Abby Wilson Published
-
A Christmas Carol(ish): a 'wacky' show of 'festive chaos'
The Week Recommends Nick Mohammed's 'wacky' take on Dickens's classic tale
By Irenie Forshaw, The Week UK Published
-
London Stock Exchange's mass exodus
The UK's stock market is shrinking at its fastest rate since 2010 with companies flocking to US and Europe
By Richard Windsor, The Week UK Published
-
ADHD drugs shortage: what's behind it?
The Explainer Supply chain issues and 'tripling' of prescriptions concerns GPs as problems getting medication become 'desperate'
By The Week UK Published
-
Cannabinoid hyperemesis syndrome: a rare but troubling health risk for cannabis users
The Explainer The illness is sending some chronic marijuana users to emergency care for painful persistent vomiting
By Theara Coleman, The Week US Published
-
Pink cocaine: the new drug cocktail responsible for an increasing number of deaths
In the Spotlight The substance has been linked to the death of Liam Payne and named in a lawsuit against Sean 'Diddy' Combs
By Justin Klawans, The Week US Published
-
Scottish drug deaths: what's gone wrong?
The Explainer The latest figures show an increase in drug misuse deaths in Scotland
By Richard Windsor, The Week UK Published
-
Deadly 'brain-eating' amoebas could be spreading thanks to climate change
Under the Radar Naegleria fowleri causes rare and lethal infection, but recent uptick in cases suggests it is thriving in warming waters
By Harriet Marsden, The Week UK Last updated
-
Mushroom edibles are tripping up users
the explainer The psychedelics can sometimes have questionable components
By Devika Rao, The Week US Published
-
Rapamycin: the popular drug for longevity among biohackers
Under the Radar Living longer may be getting easier
By Devika Rao, The Week US Published
-
Pharmaceutical companies are warning of a rise in knockoff drugs
Under the Radar The World Health Organization is also urging consumers to be cautious
By Justin Klawans, The Week US Published